Literature DB >> 10215327

Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura.

M Noris1, P Ruggenenti, A Perna, S Orisio, J Caprioli, C Skerka, B Vasile, P F Zipfel, G Remuzzi.   

Abstract

Familial hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) carry a very poor outcome and have been reported in association with decreased serum levels of the third complement component (C3). Uncontrolled consumption in the microcirculation, possibly related to genetically determined deficiency in factor H--a modulator of the alternative pathway of complement activation--may account for decreased C3 serum levels even during disease remission and may predispose to intravascular thrombosis. In a case-control study by multivariate analysis, we correlated putative predisposing conditions, including low C3 serum levels, with history of disease in 15 cases reporting one or more episodes of familial HUS and TTP, in 25 age- and gender-matched healthy controls and in 63 case-relatives and 56 control-relatives, respectively. The relationship between history of disease, low C3, and factor H abnormalities was investigated in all affected families and in 17 controls. Seventy-three percent of cases compared with 16% of controls (P < 0.001), and 24% of case-relatives compared with 5% of control-relatives (P = 0.005) had decreased C3 serum levels. At multivariate analysis, C3 serum level was the only parameter associated with the disease within affected families (P = 0.02) and in the overall study population (P = 0.01). Thus, subjects with decreased C3 serum levels had a relative risk of HUS or TTP of 16.56 (95% confidence interval [CI], 1.66 to 162.39) within families and of 27.77 (95% CI, 2.44 to 314.19) in the overall population, compared to subjects with normal serum levels. Factor H abnormalities were found in four of the cases, compared with three of the healthy family members (P = 0.02) and none of the controls (P = 0.04) and, within families, factor H abnormalities were correlated with C3 reduction (P < 0.05). Reduced C3 clusters in familial HUS and TTP is likely related to a genetically determined deficiency in factor H and may predispose to the disease. Its demonstration may help identify subjects at risk in affected families.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215327     DOI: 10.1681/ASN.V102281

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  31 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

3.  Hemolytic uremic syndrome due to homozygous factor H deficiency.

Authors:  Sidharth Kumar Sethi; Dragon-Durey Marie-Agnes; Neelam Thaker; Pankaj Hari; Arvind Bagga
Journal:  Clin Exp Nephrol       Date:  2009-07-01       Impact factor: 2.801

Review 4.  Mechanisms of immune-deposit formation and the mediation of immune renal injury.

Authors:  Masaomi Nangaku; William G Couser
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

5.  The burden of genetic disease on inpatient care in a children's hospital.

Authors:  Shawn E McCandless; Jeanne W Brunger; Suzanne B Cassidy
Journal:  Am J Hum Genet       Date:  2003-12-12       Impact factor: 11.025

6.  Risk factors for poor renal prognosis in children with hemolytic uremic syndrome.

Authors:  Alessandra Gianviti; Alberto E Tozzi; Laura De Petris; Alfredo Caprioli; Lucilla Ravà; Alberto Edefonti; Gianluigi Ardissino; Giovanni Montini; Graziella Zacchello; Alfonso Ferretti; Carmine Pecoraro; Tommaso De Palo; Angela Caringella; Maurizio Gaido; Rosanna Coppo; Francesco Perfumo; Nunzia Miglietti; Ilse Ratsche; Rosa Penza; Giovambattista Capasso; Silvio Maringhini; Salvatore Li Volti; Carmen Setzu; Marco Pennesi; Alberto Bettinelli; Leopoldo Peratoner; Ivana Pela; Elio Salvaggio; Giuliana Lama; Salvatore Maffei; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2003-10-31       Impact factor: 3.714

7.  Hemolytic uremic syndrome associated with group A beta-hemolytic streptococcus.

Authors:  Amy B Shepherd; April L Palmer; Steven A Bigler; Radhakrishna Baliga
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

8.  Mannan-binding lectin in children with Escherichia coli O157:H7 haemmorrhagic colitis and haemolytic uraemic syndrome.

Authors:  F Proulx; E Wagner; B Toledano; H Decaluwe; E G Seidman; G-E Rivard
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

9.  Recurrent hemolytic uremic syndrome.

Authors:  G Lakshminarayana; R Rajesh; A Jojo; G Kurian; V N Unni
Journal:  Indian J Nephrol       Date:  2008-07

Review 10.  Post-bone marrow transplant thrombotic microangiopathy.

Authors:  F Obut; V Kasinath; R Abdi
Journal:  Bone Marrow Transplant       Date:  2016-03-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.